Company profile
Welcome - NovaBiotics is a leading clinical-stage biotechnology company
A leading clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat diseases
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
AA | Transaction MzQ0MjM2ODMxNWFkaXF6a2N4 | Paper/PDF filed
Published 12 Nov 2024 06:56
AD01 | Transaction MzQ0MTczNjQ5NGFkaXF6a2N4
Published 01 Nov 2024 10:41
CS01 | Transaction MzQzNDkzMjQwNmFkaXF6a2N4
Published 09 Sep 2024 09:59
AA01 | Transaction MzQzMzQ3MzU3N2FkaXF6a2N4
Published 27 Aug 2024 14:01
Company registered at Companies House
1 Oct 2020 to 30 Sep 2021
Nylexa is a repurposed therapy, already in advanced development for chest infections in CF patients, that can be rapidly deployed as a treatment for COVID-19\. Nylexa is unique and potentially game-changing, because it has multiple targets; the nSARS-CoV-2 virus, the immune response to the infection and also the complications of intractable bacterial infe...
1 Jan 2019 to 31 Mar 2022
Novamycin is a novel antifungal drug being developed by NovaBiotics for front-line treatment of medically unmet, tissue and bloodstream (i.e. invasive) fungal infections caused by difficult to treat moulds and yeasts (including Aspergillus fumigatus and Candida auris). Untreated, invasive fungal disease (IFD) has a mortality rate of 100% and even with tre...
1 Nov 2016 to 31 Oct 2018
To transfer essential pharmaceutical formulation knowledge and expertise to facilitate the development of a best in class treatment for oral thrush (Oropharyngeal candidiasis).
